Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cha, Eui-Joon | - |
dc.contributor.author | Jang, Eue Soon | - |
dc.contributor.author | Sun, In-Cheol | - |
dc.contributor.author | Lee, In Joon | - |
dc.contributor.author | Ko, Jeong Hoon | - |
dc.contributor.author | Kim, Young Il | - |
dc.contributor.author | Kwon, Ick Chan | - |
dc.contributor.author | Kim, Kwangmeyung | - |
dc.contributor.author | Ahn, Cheol-Hee | - |
dc.date.accessioned | 2024-01-20T16:03:14Z | - |
dc.date.available | 2024-01-20T16:03:14Z | - |
dc.date.created | 2021-09-04 | - |
dc.date.issued | 2011-10-30 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/129873 | - |
dc.description.abstract | A fabrication method of Cy5.5-MMP substrate and PEG conjugated iron oxide nanoparticles with thin silica coating (PCM-CS) and its potential as an 'activatable' dual imaging probe for tumor imaging is described in this report. PCM-CS showed an intensity-averaged diameter of 43.1 +/- 6.3 nm by dynamic light scattering without any noticeable aggregation over 7 days. Fluorescence of Cy5.5 on the surface of nanoparticles was fully quenched and the quenching efficiency was 97.2%. PCM-CS showed protease specific fluorescence recovery in vitro caused from the specific peptide cleavage by MMP-2 and the probe displayed the sensitivity on 0.5 nM or less enzyme concentration. Tumor was successfully visualized by NIRF and MRI in vivo by intravenously injected PCM-CS. NIRF signal of tumor was gradually increased up to 12 h post injection and the intensity of tumor was about 3-4 times higher than normal tissue. NIRF signal at MMP-2 inhibitor treated tumor was clearly lower than tumor without inhibitor due to the insufficient peptide cleavage. NIRF signal at excised tumor was 5-10 times stronger than other organs. Noticeable darkening in magnetic resonance image was observed at the tumor region and the image was gradually darkened at 12 h post injection of PCM-CS. The maximum signal difference between tumor region and healthy muscle was 34%. (C) 2011 Elsevier B.V. All rights reserved. | - |
dc.language | English | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.subject | IN-VIVO | - |
dc.subject | FLUORESCENT NANOPARTICLES | - |
dc.subject | THERAPY | - |
dc.title | Development of MRI/NIRF 'activatable' multimodal imaging probe based on iron oxide nanoparticles | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jconrel.2011.07.019 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CONTROLLED RELEASE, v.155, no.2, pp.152 - 158 | - |
dc.citation.title | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.volume | 155 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 152 | - |
dc.citation.endPage | 158 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000297102200007 | - |
dc.identifier.scopusid | 2-s2.0-80054092195 | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Article; Proceedings Paper | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | FLUORESCENT NANOPARTICLES | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | MRI | - |
dc.subject.keywordAuthor | Optical imaging | - |
dc.subject.keywordAuthor | Activatable | - |
dc.subject.keywordAuthor | Dual imaging | - |
dc.subject.keywordAuthor | Iron oxide | - |
dc.subject.keywordAuthor | Core-shell nanoparticle | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.